Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew Spaltenstein is active.

Publication


Featured researches published by Andrew Spaltenstein.


Bioorganic & Medicinal Chemistry Letters | 2010

Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion.

Maosheng Duan; Mark Edelstein; Robert Ferris; Wieslaw M. Kazmierski; Andrew Spaltenstein; Pat Wheelan; Zhiping Xiong

Several series of carbamate, urea and carboxamide-based CCR5 antagonists have been discovered via optimizations at the amine portion of lead compound 2. All compounds were evaluated for their antiviral activities. Lead urea 29 showed good pharmacokinetic properties, justifying further development of this series.


Archive | 1998

Prodrugs os aspartyl protease inhibitors

Michael R. Hale; Roger D. Tung; Christopher T. Baker; Andrew Spaltenstein; Eric S. Furfine; Istvan Kaldor; Wieslaw M. Kazmierski


Archive | 2008

Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents

Michael R. Hale; Roger D. Tung; Stephen Price; Robin David Wilkes; Wayne C. Schairer; Ashley Nicholas Jarvis; Andrew Spaltenstein; Eric S. Furfine; Vicente Samano; Istvan Kaldor; John Miller; Michael Stephen Brieger


Archive | 2006

Inhibidores de aspartil proteasa.

Michael Stephen Brieger; Eric S. Furfine; Michael R. Hale; Ashley Nicholas Jarvis; Istvan Kaldor; John Miller; Stephen Price; Vicente Samano; Wayne C. Schairer; Andrew Spaltenstein; Roger D. Tung; Robin David Wilkes


Archive | 2001

SULFONAMIDAS Y AMIDAS COMO INHIBIDORES DE ASPARTIL PROTEASA

Andrew Spaltenstein; Michael R. Hale; Christopher T. Baker; Timothy A Stammers; Francois Matais; John Miller; Vicente Somano; Clarence Webster Andrews; Ronald G. Sherrill; Eric S. Furfine


Archive | 2000

Inhibiteurs d'aspartyl protease

Michael R. Hale; Roger D. Tung; Stephen Price; Robin David Wilkes; Wayne C. Schairer; Ashley Nicholas Jarvis; Andrew Spaltenstein; Eric S. Furfine; Vicente Samano; Istvan Kaldor; John Miller; Michael Stephen Brieger


Archive | 2000

Aspartyl-Protease Inhibitoren Aspartyl protease inhibitors

Stephen Michael Raleigh Brieger; Steven Eric Durham Furfine; Robin Michael Bedford Hale; Ashley Nicholas Jarvis; Istvan Kaldor; Franklin John Durham Miller; Stephen Price; Vicente Chapel Hill Samano; Carl Wayne Westborough Schairer; Andrew Spaltenstein; Roger Beverly Tung; Robin David Wilkes


Archive | 1999

Sulfonamide als aspartyl-protease-inhibitoren Sulfonamides as aspartyl protease inhibitors

Iii Clarence W. Andrews; Eric S. Furfine; R. Michael Hale; Thomas Gregory Lowen; Ronald G. Sherrill; Andrew Spaltenstein


Archive | 1998

Promedicaments des inhibiteurs de l'aspartyl-transferase

Christopher T. Baker; Eric S. Furfine; Michael R. Hale; Istvan Kaldor; Wieslaw M. Kazmierski; Andrew Spaltenstein; Roger D. Tung


Archive | 1998

Promedicaments de la classe des inhibiteurs d'aspartyle protease

Michael R. Hale; Roger D. Tung; Christopher T. Baker; Andrew Spaltenstein; Eric S. Furfine; Istvan Kaldor; Wieslaw M. Kazmierski

Collaboration


Dive into the Andrew Spaltenstein's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge